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Intranasal immunization of mice with chimeric VP6 and the adjuvant LT(R192G) consistently elicits >95% reductions in fecal rotavirus
shedding following challenge. To determine the association between mucosal antibody and protection, we immunized BALB/c wt and J chain
knockout (Jch/) mice with VP6 and either LT(R192G) or cholera toxin (CT). Both strains developed nearly equal levels of serum rotavirus
IgG, but Jch/ mice, which cannot transport dimeric IgA across epithelial cell surfaces, developed >4-fold higher levels of serum rotavirus IgA.
Stool rotavirus IgA was present in wt but undetectable in Jch/ mice. When challenged with rotavirus strain EDIM, reductions in rotavirus
shedding were nearly identical in VP6-immunized wt and Jch/ mice (i.e., 97% and 92%, respectively; P > 0.01). Th1 CD4 T cell responses
were also detected in VP6-immunized animals based on high levels of IFN-g and IL-2 found after in vitro VP6 stimulation of spleen cells.
Therefore, protection induced by intranasal immunization of mice with VP6 and adjuvant does not depend on intestinal rotavirus IgA antibody but
appears to be associated with CD4 T cells.
D 2005 Elsevier Inc. All rights reserved.Keywords: Rotavirus; VP6 immunization; J chain knockout mice; Intestinal IgAIntroduction
Rotaviruses are the single most important cause of severe
infantile gastroenteritis. It has been estimated that these viruses
are responsible for ca. 600,000 deaths in the world annually
(Parashar et al., 2003) and remain a high priority for vaccine
development. To date, vaccines being evaluated in children to
prevent rotavirus disease have all been live, attenuated
rotaviruses administered orally. To avoid possible side effects
of live vaccines (Dennehy, 2005; Glass et al., 2004), a number
of non-living rotavirus vaccine candidates have been developed
and are being assessed in animal models.
One such candidate is virus-like particles (VLPs). These
contain the major structural proteins of rotavirus which are0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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expressed proteins combine to form particles that are structur-
ally equivalent to rotavirus particles made in vivo. VLPs
containing the inner capsid proteins, VP2 and VP6, either with
or without the outer capsid neutralization proteins VP4 or VP7,
have been used in animal models to determine their protective
effects against rotavirus infection or disease. Rabbits parenter-
ally immunized with homologous VLPs containing rotavirus
proteins 2/4/6/7 were better protected against rotavirus
challenge than those given 2/6 VLPs, although VP4 and VP7
were not absolutely required for protection against infection
(Ciarlet et al., 1998; Crawford et al., 1999). When heterologous
VLPs of any combination were used, protection decreased, and
if rabbits were immunized by the intranasal route, no protection
against infection was observed (Bertolotti-Ciarlet et al., 2003).
A number of groups have used the adult mouse model of
rotavirus infection (Ward et al., 1990) to evaluate VLPs as
vaccines. Several reports indicated that VLPs given to mice6) 338 – 347
www.e
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shedding after murine rotavirus challenge as compared to
unimmunized mice and VP7 and VP4 are not necessary to
achieve protection in this shedding model (Bertolotti-Ciarlet et
al., 2003; Crawford et al., 1999; Jiang et al., 1999; O’Neal et
al., 1997, 1998; Siadat-Pajouh and Cai, 2001). When VLPs
were given orally, protection decreased significantly in some
studies and was absent in others (Bertolotti-Ciarlet et al., 2003;
O’Neal et al., 1997). In a passive protection model where
mouse dams were immunized, 2/6 VLPs did not prevent illness
in pups, but inclusion of VP7 protected against rotavirus
diarrhea (Coste et al., 2000). In the gnotobiotic pig model,
VLPs administered intranasally were not protective but boosted
protection from rotavirus shedding and diarrhea when admin-
istered after initial infection with an attenuated live rotavirus
(Azevedo et al., 2004; Gonzalez et al., 2004; Iosef et al., 2002;
Nguyen et al., 2003; Yuan and Saif, 2002; Yuan et al., 2000,
2001).
We have evaluated a new vaccine candidate based solely on
one rotavirus protein, i.e., VP6, expressed in E. coli as a
chimeric protein containing maltose binding protein (MBP).
We subsequently reported that intranasal or oral immunization
of mice with MBP0VP6 proteins from either a murine (EDIM)
or human (CJN) strain of rotavirus protected mice of different
strains and different haplotypes from shedding when chal-
lenged with either of two different stains of murine rotavirus
(EDIM or EMcN) (Choi et al., 1999, 2002a). In all studies with
VLPs and VP6 vaccine candidates, the levels of protection
were dependent on the route of immunization, dose of
immunogen and co-administration of an effective adjuvant
(Bertolotti-Ciarlet et al., 2003; Choi et al., 2002b). The most
effective adjuvants for mucosal immunization have been
cholera toxin (CT) and E. coli heat labile toxin (LT) or
genetically attenuated versions such as LT(R192G) (Choi et al.,
2002b; O’Neal et al., 1998).
Protection in most studies with VLPs in rabbits, mice or
gnotobiotic pigs correlated with levels of intestinal antibody
(Gonzalez et al., 2004; Nguyen et al., 2003; O’Neal et al.,
1997; Yuan and Saif, 2002), although T cell responses were not
reported. The most abundant antibody at the intestinal surface
is IgA but lower levels of IgM and IgG antibody producing
cells can be found in the intestinal lamina propria (Mestecky et
al., 2005). Dimeric IgA and pentameric IgM, but not IgG, are
actively transported across the epithelial cell to the lumen of
the intestine. Dimeric IgA, containing a J chain, binds to the
polymeric Ig receptor (pIgR) expressed on the basolateral side
of intestinal epithelial cells. After binding, the pIgR-antibody
complex is transported through the epithelial cell and released
from the apical surface into the lumen. During transport, the
receptor is proteolytically cleaved resulting in the formation of
secretory IgA (sIgA) (Kaetzel and Mostov, 2005). A geneti-
cally engineered mouse strain has been developed in which the
J chain has been disrupted (Hendrickson et al., 1995). In these
mice, transport of dimeric IgA by the pIgR is impaired.
Although some forms of IgA can be detected in mucosal
secretions, these mice lack dimeric or higher polymeric forms
of IgA at mucosal surfaces which are thought to be necessaryfor the ability of the antibody to function (Hendrickson et al.,
1996). In a study using these J chain knockout mice (Jch/),
intranasal immunization with 2/6 VLPs and CT as adjuvant was
reported to confer little protection against rotavirus shedding as
compared to that found in immunologically normal mice. This
study concluded that transport of non-neutralizing antibody via
the pIgR-dependent pathway was necessary for protection after
immunization with 2/6 VLPs (Schwartz-Cornil et al., 2002).
Mucosal immunization with MBP0VP6, either intranasal or
oral, was found to elicit serum rotavirus IgG responses but small
or undetectable levels of serum or stool rotavirus IgA (Choi et
al., 1999). Using in vivo depletion of either CD8 or CD4 T cells
in B cell-deficient mice, as well as adoptive transfer of immune
cells into chronically shedding Rag-1 mice, we found that CD4
T cells were the only lymphocytes needed for protection against
rotavirus shedding after intranasal immunization with
MBP0VP6/LT(R192G) (McNeal et al., 2002). Subsequently,
we also found that protection against EDIM shedding was
retained after oral MBP0VP6/LT(R192G) immunization of B
cell-deficient mice depleted of CD8 T cells but was lost when
these orally immunized mice were depleted of CD4 T cells prior
to challenge (unpublished results). This suggested that CD4 T
cells were the only lymphocytes required for protection after
either intranasal or oral immunization of mice with MBP0VP6/
LT(R192G). Based on possible differences in the importance of
antibody after intranasal immunization with VLPs versus
chimeric VP6, coupled with evidence for large differences in
the levels of protection found after oral immunization, these two
immunogens may induce different protective immune
responses.
In order to verify this hypothesis, the present study was
conducted to determine if transport of intestinal dimeric IgA or
the presence of this antibody at the luminal surface was
necessary for the protection induced in mice after immuniza-
tion with chimeric VP6. Normal wild-type (wt) BALB/c mice
and J chain knock out mice (Jch/) were immunized with
MBP0VP6 protein and either LT(R192G) or CT and subse-
quently challenged with the EDIM strain of murine rotavirus.
Protection against rotavirus shedding was nearly equivalent in
the two strains of mice. Immune responses were measured by
determining antibody responses in wt and Jch/ mice.
Although both serum and intestinal rotavirus IgA levels were
different in the two mouse strains prior to challenge as
expected, memory T cell populations were induced to produce
similar cytokine profiles after in vitro stimulation. Therefore,
protection after intranasal immunization with MBP0VP6 did
not depend on the transport by epithelial cells or the presence
of dimeric IgA at the intestinal surface.
Results
Rotavirus IgA is not detectable in stools of Jch/ mice after
intranasal immunization with MBP0VP6 and adjuvants
Prior to determining the effects of the absence of J chain
on protection of BALB/c mice against EDIM shedding after
intranasal MBP0VP6 immunization, the levels of serum and
Fig. 1. Effect of intranasal immunization with MBP0VP6/LT(R192G) on
rotavirus shedding in BALB/c wt (A) and Jch/ (B) mice. Groups of adul
mice were immunized with 2 doses of 9 Ag MBP0VP6 and 10 Ag LT(R192G)
At 4 weeks after the second dose, mice were challenged with 105 SD50 of w
EDIM, and the mean shedding of rotavirus antigen (ng/mouse/day) was
measured. The limit of detection for each stool specimen was 1 ng/ml. The
percent reduction in shedding in the immunized mice during the first 7 days
after challenge was determined relative to that found in the unimmunized mice
for each strain. Standard errors of the mean are shown for each day for the mice
within a group.
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BALB/c wt and Jch/ mice in specimens collected on the
day before EDIM challenge. For this, mice were intranasally
immunized with two doses of 9 Ag of MBP0VP6 and either
5 Ag of CT or 10 Ag of LT(R192G), separated by 2-week
intervals. Four weeks after the second immunization, serum
and stool samples were collected for antibody measurements.
Both immunized BALB/c wt and Jch/ mice developed
similar amounts of serum rotavirus IgG. These responses
were not significantly different whether LT(R192G) or CT
was used as adjuvant and also not significantly different when
compared between wt and Jch/ mouse strains (Table 1).
Wt mice developed modest amounts of serum rotavirus IgA
but Jch/ mice contained significantly greater (P < 0.0001)
levels, regardless of which adjuvant was used (Table 1). This
result implied that Jch/ mice have impaired hepatic and
intestinal transport of dimeric IgA and confirmed reports that
IgA levels in serum become elevated in these animals
(Hendrickson et al., 1995, 1996).
Stool rotavirus IgA levels were low but measurable after
immunization of wt BALB/c mice (Table 1). Differences in
levels found when CT or LT(R192G) was used as the adjuvant
were not significant (P = 0.015). As expected Jch/mice had
undetectable levels of stool rotavirus IgA, and these were
significantly different (P < 0.0001) compared to wt mice. This
result confirms that Jch/ mice cannot transport dimeric IgA
to mucosal surfaces. Very little stool rotavirus IgG was detected
and the levels were not significantly different between the two
strains of immunized mice whether LT(R192G) or CTwas used
as adjuvant (Table 1).
Protection against rotavirus shedding stimulated by intranasal
immunization with MBP0VP6 and adjuvant is unaffected by
the absence of intestinal rotavirus IgA
To determine if intranasal immunization with MBP0VP6
and adjuvant would protect Jch/ mice from rotavirus
shedding after challenge, groups of unimmunized and immu-
nized wt and Jch/mice were challenged with EDIM 4 weeks
after the second immunization. Stools were collected daily from
each mouse to determine shedding of rotavirus. Unimmunized
wt mice shed virus starting 1 day after challenge with a peak on
day 5 and then resolved the infection by day 8 (Fig. 1A). TheTable 1
Serum and stool rotavirus antibody responses after intranasal immunization with MBP0VP6a
Mouse strain Immunogen Serum IgGb (ng/ml) Serum IgAb (ng/ml) Stool IgGb (ng/ml) Stool IgAb (ng/ml
BALB/c wt None <100 <100 <5 <5
MBP0VP6/LT(R192G) 299,417 T 143,769 263 T 143 6 T 3 33 T 28
MBP0VP6/CT 341,596 T 197,508 273 T 201 8 T 5 104 T 111
BALB/c Jch/ None <100 <100 <5 <5
MBP0VP6/LT(R192G) 247,736 T 101,066 1162c T 757 6 T 2 <5c
MBP0VP6/CT 250,005 T 95,094 1377c T 622 13 T 11 <5c
a Groups of 5 to 12 mice were intranasally immunized with two doses of 9 Ag MBP0VP6 and either 10 Ag of LT(R192G) or 5 Ag CT. Four weeks after the second
dose, serum and stool samples were obtained and the amount of rotavirus IgG or IgA was determined by ELISA.
b Geometric mean titers T standard deviation. The limit of detection was 100 ng/ml and 5 ng/ml for serum and stool antibodies, respectively, and these values were
used to calculate geometric mean titers for antibody levels of <100 or <5.
c Significantly different from BALB/c wt mice ( P < 0.0001).t
.
tunimmunized Jch/ mice displayed a similar pattern of
rotavirus shedding for the first 7 days where shedding peaked
at days 4–5 and decreased by day 7. However, these mice were
unable to fully resolve shedding for the 22 days they were)
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unimmunized Jch/ on 14 of the 22 days that stool samples
were collected with the lowest percentage of animals shedding
on any 1 day being 70%. The level of antigen determined in the
stools of individual animals after day 7 was ca. 100-fold above
the limit of detection for this assay. In addition, this experiment
was independently repeated two times with the same result of
continued shedding. From these three experiments, 100% of a
total of 26 unimmunized Jch/ mice experienced chronic
shedding.
When MBP0VP6/LT(R192G)-immunized wt and Jch/
mice were challenged with EDIM, the amount of shedding was
drastically reduced in both mouse strains when compared to the
unimmunized animals of each group. Immunized wt mice shed
reduced amounts of virus for 1 to 4 days, and overall, the amount
of shedding was reduced by >99% during the first 7 days after
challenge (Fig. 1A). Although immunized Jch/ mice shed
detectable quantities of rotavirus for more days than immunized
wtmice and had additional days where low levels (<10 ng/ml) of
rotavirus were detected in their stools, the amount of shedding
during the 7 days after challenge was still reduced by 97%
compared to that found in unimmunized Jch/mice (Fig. 1B).
This experiment was repeated two additional times, and
shedding was reduced in MBP0VP6/LT(R192G) immunized
mice by 97 and 99% in wt mice and 87 and 93% in Jch/mice
for averages of 97 and 92%, respectively.
To determine if the protection levels were different in
BALB/c wt and Jch/ mice, the percent reduction in
shedding was determined for each immunized mouse of both
strains as compared to the mean shedding measured for the
unimmunized groups of each strain. These individual percent
reductions in shedding and the mean reduction for eachFig. 2. Percent reductions in rotavirus shedding for MBP0VP6/LT(R192G) immuni
separate experiments (A, B, C). Groups of mice were immunized as described in Fig
or 6) mouse in a strain as compared to the mean shedding determined for all the unim
group (wt or Jch/) relative to the unimmunized animals in each experiment. *
( P=0.03) different than percent reductions of wt mice.group are shown in Fig. 2 for each of the three experiments.
The percent reductions in shedding induced in the
MBP0VP6 immunized Jch/ mice were not significantly
different from the levels found in the immunized wt mice in
the first two experiments when analyzed using a t test based
on the Satterthwaite comparisons of unequal variances. In the
third experiment, when the wt mice were compared to the
Jch/ mice using this method, differences in the levels of
protection reached significance but just barely (P = 0.03).
These analyses indicate that the levels of protection measured
by the percent reductions in rotavirus shedding after
challenge in immunized Jch/ mice compared to unimmu-
nized Jch/ mice are similar to the protection levels
measured in immunized wt compared to unimmunized wt
mice.
When CT was used as the adjuvant during intranasal
immunization with MBP0VP6, protection against shedding
was also not significantly different in wt (97% reduction) and
Jch/ (91% reduction) mice. Thus, the use of either adjuvant
with MBP0VP6 resulted in significant (P < 0.0001) protection
against shedding in each strain of mice.
Similar populations of memory CD4 T cells are stimulated after
intranasal immunization of BALB/c wt and Jch/ mice with
MBP0VP6/LT(R192G)
Because we have found that CD4 T cells are the only
lymphocytes needed for protection after intranasal immuniza-
tion of BALB/c wt and B cell-deficient (JHD) mice with
MBP0VP6 and LT(R192G), it was of interest to examine the
type of memory CD4 T cell response present at the time of
challenge in immunized BALB/c wt and Jch/ mice.zed BALB/c wt and Jch/ mice after EDIM challenge as determined in three
. 1. The percent reduction in shedding was calculated for each immunized (n =5
munized animals (n =5 to 12) of each strain. Mean protection is shown for each
Not significantly different than percent reductions of wt mice. #Significantly
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already described and 4 weeks after the second immunization
(the normal day of challenge), spleen cells were obtained from
unimmunized and immunized animals. These cells were then
either not stimulated or stimulated in vitro with MBP0VP6.
After 24 h, the last 4 in the presence of brefeldin A,
supernatants were harvested and analyzed for cytokine
secretion by ELISA, and the cells were stained for intracellular
cytokine production. IL-2 was measured as an indicator of a
recall response showing T cell recognition of the VP6 antigen.
IFN-g production was measured as an indicator of a Th1
response, and IL-4 and IL-5 were measured to indicate a Th2
response.
Unstimulated cultures produced undetectable to low levels
of all cytokines measured. After in vitro stimulation with
MBP0VP6, spleen cells from unimmunized BALB/c wt and
Jch/ mice both produced little or no detectable IL-2, IL-4,
IL-5 or IFN-g as measured in the harvested supernatants (Table
2). Cells obtained from immunized animals of both mouse
strains were stimulated to produce large quantities of IFN-g
and IL-2, while only undetectable to low levels of IL-4 and IL-
5 were measured in these cultures (Table 2).
To determine if CD4 T cells were secreting these cytokines,
the cells were stained for surface CD4 and intracellular cytokine
accumulation, then analyzed by flow cytometry. No measurable
cytokine production was detected in the unstimulated cells from
any group (results not shown). After in vitro stimulation of
spleen cells from unimmunized mice of either strain with
MBP0VP6, <0.3% of CD4 cells contained detectable IFN-g or
IL-2. However, much greater numbers of splenic CD4 cells from
VP6-immunized wt and Jch/ mice were induced to make
these two cytokines (Figs. 3A and B). No measurable increases
in IL-4 and IL-5 producing CD4 T cells were stimulated in
immunized mice of either strain (results not shown).This result
was expected since very low levels of these cytokines were
measured in the supernatants. In summary, MBP0VP6 immu-
nization of BALB/c wt and Jch/mice elicited the production
of rotavirus-specific, memory CD4 T cells, and in each case,
these cells could be stimulated to predominantly express Th1
cytokines, thus demonstrating that CD4 T cell responses in
Jch/ mice are similar to those found in wt mice after VP6
immunization.Table 2
Cytokines secreted by spleen cells obtained from unimmunized and MBP0VP6/LT
Mouse strain Stimulated I
BALB/c wt unimmunized –
+MBP0VP6
BALB/c wt MBP0VP6/LT(R192G) immunized –
+MBP0VP6 3
BALB/c Jch/ unimmunized –
+MBP0VP6
BALB/c Jch/ MBP0VP6/LT(R192G) immunized –
+MBP0VP6 2
a Groups of 2 to 6 mice were intranasally immunized with two doses of 9 Ag MBP
from 2–6 animals were isolated and pooled. Cells were placed in culture and either
harvested and cytokine levels determined by ELISA. Data shown is representative
b The limit of detection was 10 pg/ml for IL-2, IL-4, and IL-5 and 50 pg/ml forDiscussion
Two major classes of rotavirus vaccines have been and are
continuing to be developed to prevent this deadly disease.
The initial candidates were all live, attenuated rotavirus
strains which, after oral delivery, were anticipated to mimic
the excellent protection against severe rotavirus disease
elicited by natural infection. All rotavirus vaccine candidates
evaluated in human trials to date have been live viruses, and
two of these candidate vaccines are expected to be utilized
throughout the world within the next few years. The other
major class of rotavirus vaccines under development consists
of either inactivated virus or subunit vaccines that can be
expressed from biological vectors or delivered directly.
Although many of the candidate vaccines from both classes
have been found to provide excellent protection against
rotavirus disease or infection in human and animal studies,
the mechanisms used to elicit protection are not fully
understood for any rotavirus vaccine candidate. One consis-
tent theme of studies designed to reveal these mechanisms is
to identify the memory cells responsible for protection,
particularly to define the roles of CD8 and CD4 T cells as
well as B cells and the antibodies they produce. The adult
mouse model for studies on active immunity was designed to
help define the importance of these potential effectors of
protection in resolution and prevention of rotavirus infection
(Ward et al., 1990).
The role of antibody in the resolution of a primary
rotavirus infection has been demonstrated in a number of
studies using this adult mouse model. For example, rotavirus
infection in mice lacking B cells, such as AMt or JHD
strains, can result in low level chronic shedding (McNeal et
al., 1995). In B cell-deficient mice, CD8 T cells are thought
to be the major effectors needed to resolve or reduce
rotavirus shedding because when these cells are depleted,
chronic high level shedding was observed (Franco and
Greenberg, 1995; McNeal et al., 1995). Prolonged shedding
after primary rotavirus infection has also been observed in
mice lacking functional T cells such as ah T cell receptor
knockout mice or nude mice (VanCott et al., 2001). From
these studies, it was concluded that T cells were necessary
for development of rotavirus antibody after infection, and(R192G) immunized BALB/c wt and Jch/ mice after in vitro stimulationa
L-2b (pg/ml) IFN-gb (pg/ml) IL-4b (pg/ml) IL-5b (pg/ml)
18 107 55 17
29 9463 64 23
19 234 30 21
319 58,468 80 74
<10 15 101 20
<10 2744 85 20
<10 801 63 13
111 145,568 163 147
0VP6 and 10 Ag of LT(R192G). Four weeks after the second dose, spleen cells
left unstimulated or stimulated with 9 ug MBP:VP6 for 24 h. Supernatants were
of two independent experiments.
IFN-g assays.
Fig. 3. Intracellular staining of spleen cells obtained from unimmunized and
MBP0VP6/LT(R192G) immunized BALB/c wt and Jch/ mice after in vitro
stimulation. Cells were isolated from 2 to 6 animals and pooled. Cultures of
spleen cells were stimulated with 9 Ag MBP0VP6 or left unstimulated for 24 h.
Brefeldin A was added for the last 4 h of culture. Cells were harvested and
stained for CD4 and IFN-g or IL-2. Cells were gated on the lymphocyte
population, and the percent of CD4 cells producing cytokines was measured as
shown in the upper right quadrant. Unstimulated cells had no measurable
cytokine accumulation (data not shown). The top rows are cells from
unimmunized mice while the bottom rows are cells from MBP0VP6
immunized animals. (A) IL-2, (B) IFN-g. Data shown are representative of
two independent experiments.
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found in these animals were not sufficient to fully resolve
rotavirus shedding.In the present study, Jch/ mice were used to determine
the importance of intestinal rotavirus IgA after immunization
with our new VP6 rotavirus vaccine candidate. These mice
cannot transport dimeric IgA through epithelial cells and,
therefore, lack this functional antibody at mucosal surfaces
including the intestinal lumen. In a previous study conducted
by Schwartz-Cornil et al. (2002), Jch/ mice were infected
with the ECw strain of rotavirus and shedding was measured
after infection. The day of viral clearance was deduced from a
mathematical formula derived from the viral shedding curve.
The shedding curve was based on ELISA OD units instead of
actual quantities of viral antigen, and the authors concluded
that shedding was resolved by 8 days after infection. The
authors did not collect or analyze any samples past this time
point. Shedding was reduced on day 8 in their study, but in
fact, their data still show measurable antigen shedding on this
day. Since they did not collect additional time points, it
cannot be determined if resolution really occurred in their
study. In the present study, infection of unimmunized Jch/
mice with the EDIM stain of rotavirus demonstrated a pattern
of chronic shedding when monitored for over 3 weeks after
the time of challenge. Rotavirus shedding did decrease by 7
days after infection but the Jch/ mice were unable to fully
resolve the infection and 100% of the animals continued to
shed rotavirus at levels ca.100-fold above the limit of
detection in their stools during the 22 days they were
monitored. This pattern of continued shedding was similar
to that found in B cell-deficient mice (JHD and AMt mice) that
lack all antibody (McNeal et al., 1995, 1997). Since Jch/
mice have normal serum IgG levels and elevated serum IgA
levels (Hendrickson et al., 1995, 1996) but cannot transport
dimeric IgA to the intestinal surface, the present study
demonstrates that intestinal IgA is a major effector involved
in rotavirus clearance after primary infection in mice. Without
intestinal dimeric IgA, CD8 T cells could not completely clear
the infection. In addition, when CD8 cells were depleted at
the time of challenge in Jch/ mice, high level chronic
shedding (1000- to 10,000-fold above the limit of detection)
occurred in 100% of the animals and continued for over 3
weeks after infection with EDIM (results not shown). These
results were similar to those obtained with B cell-deficient
mice depleted of CD8 cells (Franco and Greenberg, 1995;
McNeal et al., 1995).
In previous studies using IgA knockout mice, mice that
cannot make any serum or stool IgA, it was found that in the
absence of IgA, these mice were able to clear a rotavirus
infection with a slight delay as compared to wt mice. These
knockout mice were shown to have increased levels of
intestinal IgM and IgG (Harriman et al., 1999). The authors
concluded that these classes of antibody could compensate for
the absence of IgA, perhaps due to the unusually high
concentrations in this genetically modified mouse strain
(Kuklin et al., 2001; O’Neal et al., 2000). Therefore, in this
mouse strain (IgA knockout), intestinal antibody, although not
IgA, still appeared to be the major effector for rotavirus
resolution especially since shedding was resolved even when
CD8 T cells were depleted in the study by Kuklin et al. (2001).
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a previous infection, either from natural rotavirus infection or
oral vaccination with live vaccine strains, has been correlated
with the presence of serum or stool antibody in a number of
human studies (Coulson et al., 1992; Matson et al., 1993;
Ward, 1996, 2003; Ward and Bernstein, 1995). Studies in
animal models using gnotobiotic pigs, rabbits, and mice have
also shown correlations between serum and stool antibody
produced as a result of oral infection with either homotypic or
heterotypic live rotaviruses and protection against rotavirus
challenge (Conner et al., 1991, 1997; Feng et al., 1997; To et
al., 1998; Ward et al., 1992a, 1992b; Yuan et al., 1998).
Protection against rotavirus has often been found in association
with the presence of neutralizing antibody, but the importance
of this antibody is unclear since protection has also been found
in studies where neutralizing antibody against the challenge
strain was either not detected or its levels did not correlate with
protection (Ward and Bernstein, 1995; Ward et al., 1992a,
1992b, 1997).
In the present study, protection against rotavirus infection
was measured after intranasal immunization with a chimeric
VP6 protein and either LT(R192G) or CT using normal wt
mice or a mouse strain that lacked functional intestinal dimeric
IgA, Jch/ mice. This type of vaccination represents a
different route and a different immunogen when compared to a
live oral immunization. It was found that even in the absence of
intestinal transport or presence of dimeric IgA at the mucosal
surface, these animals were protected against challenge with
rotavirus. During the first 7 days following challenge, VP6
immunized Jch/ mice shed rotavirus for more days than wt
mice. In addition a low level of rotavirus antigen was detected
during 5 out of the next 15 days the mice were monitored.
However, immunized Jch/ had significant reductions in
shedding when compared to unimmunized Jch/, and the
percent reductions in shedding of virus after challenge in
animals immunized with VP6 were similar in wt and Jch/
mice. This result contrasts with that reported in the study
conducted by Schwartz-Cornil et al. (2002) using Jch/ mice
immunized with VLPs and CT as adjuvant. The authors of that
study concluded that Jch/ mice were not protected against
challenge even though the data reported indicate a reduction in
shedding in the immunized Jch/ mice.
Several features in the two studies could explain the
differences in the protection levels measured. One difference
between the studies is the antigen used for immunization. The
previous study used VLPs composed of bovine RF rotavirus
proteins VP6 and VP2 (Schwartz-Cornil et al., 2002). The
antigen used in the present study was based on one protein,
i.e.,VP6 from the murine EDIM strain. It should be noted that
when wt and Jch/ mice were intranasally immunized with
LT(R192G) and inactivated double-layered EDIM particles, an
immunogen more similar to VLPs, shedding of rotavirus was
reduced by >99% after EDIM challenge (results not shown).
Although VP6 is a highly conserved protein between
rotaviruses, VLPs are particles, and the VP6 within these
particles may be processed and presented differently than a
single protein. It is also possible that these two antigens mayinduce different protective responses. Protection after immu-
nization of mice with VLPs was associated with levels of
intestinal antibody (O’Neal et al., 1997, 1998). In gnotobiotic
pigs, protection after VLP immunization also corresponded
with the magnitude of the intestinal antibody response and
when VLPs were given after an oral immunization with an
attenuated live virus, they boosted the intestinal antibody
responses and protection against challenge (Azevedo et al.,
2004; Gonzalez et al., 2004; Iosef et al., 2002; Nguyen et al.,
2003; Yuan et al., 2000, 2001). In the study by Schwartz-
Cornil et al. (2002), immunization of wt mice with VLPs and
CT also induced a measurable intestinal antibody response
which was absent in the Jch/ mice. Intestinal antibody
lacking classical neutralizing activity has been shown to be
protective against rotavirus challenge using a monoclonal
antibody backpack model (Burns et al., 1996; Feng et al.,
2002). Therefore, mucosal IgA induced in the wt mice after
VLP immunization could be the effector of protection.
However, immunization with VP6 induces little or no
detectable intestinal antibody (Choi et al., 1999). In addition,
we have found that B cells and CD8 T cells are not necessary
for protection after VP6 immunization, and CD4 T cells were
the only lymphocytes needed for protection after intranasal
immunization of wt and B cell-deficient JHD mice with VP6
(McNeal et al., 2002). The present study further confirms that
antibody, specifically intestinal dimeric IgA antibody, is not
necessary for protection from rotavirus challenge after
intranasal immunization with VP6. However, this does not
imply that intestinal antibody would not be an effector of
protection if it was present; it only indicates that immunization
with VP6 produces a protective immune response that is not
dependent on intestinal dimeric IgA.
To date, very few studies have examined T cell responses
in mice after immunization with VLPs. In a study by
Fromantin et al. (1998), cytokine secretion after in vitro
stimulation of lymphocytes obtained from mice immunized
with VLPs with or without adjuvants was measured. The
results were that after 5 days of in vitro stimulation with
rotavirus, significant levels of IFN-g, IL-4, IL-5 and IL-2 were
detected by ELISA. The authors concluded that a mixed Th1/
Th2 immune response was generated (Fromantin et al., 1998).
Unfortunately, no direct protection studies were conducted
with the same immunization procedures. In the present study,
we measured the CD4 T cell responses generated by VP6
immunization of wt and Jch/ mice by looking at cytokine
expression after in vitro stimulation for 24 h. We found little
to undetectable levels of IL-4 and IL-5, Th2 cytokines, after
this period of stimulation. However, high levels of IL-2 and
IFN-g were detected demonstrating a predominately Th1
response. Additional cytokines may be involved in the CD4 T
cell response generated after VP6 immunization but were not
measured in the present study. However, the responses
measured showed a similar pattern in wt and Jch/ mice,
which were nearly equally protected against rotavirus chal-
lenge. The question of how CD4 T cells are involved in the
protection elicited after VP6 immunization remains to be
determined.
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with live virus, VLPs or VP6 protein can stimulate protective
responses against subsequent infection. Protection has been
correlated with the presence of intestinal antibody, CD8 T cells
and CD4 T cells depending on the type of immunogen, route of
immunization and use of different adjuvants. The differences in
the immune responses generated in animal models with
different vaccine candidates may help provide insight regarding
their effectiveness in humans.
Materials and methods
Virus
The murine stain of rotavirus (EDIM) used in this study was
originally obtained from M. Collins (Microbiological Associ-
ates, Bethesda, MD). The pool of virus used to challenge mice
after vaccination has been described previously (McNeal et al.,
2002).
Mouse strains
Breeding pairs of J chain deficient (Jch/) mice back-
crossed 10 to 12 generations into the BALB/c strain (Taconic
Laboratories, Germantown, N.Y.) were obtained from the
University of Chicago Children’s Hospital, Chicago, Illinois.
Mice were bred in our facility and used at 6 to12 weeks of age.
Age-matched wt BALB/c mice were obtained from Taconic
Laboratories. Mice were housed in microisolation cages and
shown to be rotavirus negative before use by analyzing serum
samples for the presence of rotavirus antibodies. All animal
procedures were conducted in accordance with the Cincinnati
Children’s Hospital Research Foundation Institutional Animal
Care and Use Committee.
VP6 protein used for immunization
The construction of the plasmid containing the EDIM VP6
gene, the expression of the VP6 protein in E. coli as a chimera
with maltose binding protein (MBP) and the purification of the
expressed protein, MBP0VP6, have been described previously
(Choi et al., 1999).
Immunization and challenge of mice
Mice received two intranasal immunizations, under light
sedation with isoflourane (Abbot Laboratories, Chicago, IL), of
chimeric MBP0VP6 (9 Ag) and adjuvant. The adjuvants used
in this study were either the recombinant E. coli heat labile
toxin LT(R192G) (10 Ag) obtained from Tulane University
Medical Center, New Orleans, LA or cholera toxin (CT) (5 Ag)
obtained from Sigma (St. Louis, MO). Immunizations were
separated by 2 weeks. Four weeks after the second immuni-
zation, serum and stool samples were obtained from the mice
before challenge. Groups of 5 to 12 unimmunized and groups
of 5 to 6 immunized mice were challenged with 105 SD50 of wt
EDIM by oral gavage.Detection of rotavirus antigen in stool and determination of
protection
To measure the quantities of rotavirus shed in fecal speci-
mens of mice, stool samples were collected daily for up to 22
days after rotavirus challenge. Two fecal pellets were collected
from each mouse and placed into 1.0 ml of Earle’s balanced salt
solution and stored at 20 -C until analyzed. Samples were
thawed, homogenized and centrifuged (1500  g, 5 min) to
remove debris before being analyzed for rotavirus antigen.
Quantities of rotavirus antigen shed were determined in
nanograms per milliliters of stool specimen by an enzyme-
linked immunosorbent assay (ELISA) using methods previous-
ly described (McNeal et al., 1999). Protection was measured as
the percent reduction in shedding when comparing the mean
antigen shed per mouse per day in the immunized groups to the
mean shed per mouse per day in the unimmunized groups
during the first 7 days following challenge.
Determination of rotavirus antibody titers
Serum and stool samples collected prior to challenge were
analyzed for rotavirus IgG and IgA by ELISA and expressed in
nanograms per ml as previously described (McNeal et al.,
1999). Results were expressed as the geometric mean titer of a
group T standard deviation.
Measurement of T cell responses
BALB/c wt and Jch/ mice were either unimmunized or
immunized with two doses of MBP0VP6 and LT(R192G)
separated by a 2-week interval as described above. At 4 weeks
after the second immunization, the time when these mice
would normally be challenged with EDIM, they were
sacrificed, and their spleens were removed. The spleen cells
from two to six animals in each group were pooled for analysis.
Single cell suspensions of spleen cells were made, and red
blood cells were lysed with 8.3 mg/ml of ammonium chloride
in 0.01M Tris, pH 7.4. Lymphocytes were washed and
resuspended in complete RPMI medium (Gibco, Inc., Grand
Island, NY) containing 10% fetal bovine serum, 2 mM l-
glutamine, 1 mM sodium pyruvate, 100 U/ml penicillin, 100
Ag/ml streptomycin, 2.5 Ag/ml Amphotericin B, 100 AM MEM
non-essential amino acids and 55 AM 2-mercaptoethanol.
Spleen cells (1  107 cells/ml) were cultured in 24-well tissue
culture plates (Falcon, BD Biosciences, Bedford, MA) in
complete RPMI for 24 h. Wells of cells were either left
unstimulated or stimulated with MBP0VP6 antigen (9 Ag/ml)
in vitro. During the last 4 h of culture, bredfeldin A (BD
PharMingen, San Diego, CA) was added to the cells. Super-
natants from the cultures were harvested and frozen for
determination of cytokine secretion by ELISA. To measure
cytokines secreted during the period of stimulation, ELISA kits
for IFN-g, IL-2, IL-4 and IL-5 were obtained from Pierce
Biotechnology, Inc. (Rockford, IL) and used as instructed by
the manufacturer. The levels of secreted cytokines measured
were expressed as pg/ml.
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thrin (PE) conjugated antibodies for IL-4 (clone 11B11), IL-5
(clone TRGK5), INF-g (clone XMG1.2) and IL-2 (clone JES6-
5H4) and fluorescein isothiocyanate (FITC) conjugated anti-
body to CD4 (clone RM4-4) and isotype controls from BD
PharMingen were used at concentrations recommended by the
manufacturer. After in vitro stimulation, the cells were
incubated with purified antibody to block Fc receptors (clone
2.4G2) and then stained with FITC-conjugated antibody to
CD4. After being fixed and permeabilized according to the
manufacturers instructions using a GolgiPlug kit (BD Phar-
Mingen), cells were stained with PE-conjugated antibody for
either IL-2, IL-4, IL-5 or IFN-g. Data were acquired using a
FACSCaliber and analyzed by CELLQuest software (BD
Bioscience, San Jose, CA). Cells were gated on the lymphocyte
population by forward and side scatter determination, and
200,000 cells were acquired. Measurement of T cell responses
was performed in two independent experiments.
Statistics
Comparisons in rotavirus antigen shedding within strains of
mice were carried out using two sample t tests to determine the
significance of the reduction in shedding. Differences between
groups within each strain were considered significant when the
probability levels (P) were <0.01. To determine the differences
in protection levels between strains, the percent reduction in
shedding was determined for each mouse in the immunized
groups based on the mean shedding of the unimmunized
groups, and then a t test was used to determine if the protection
rates were different between strains. Unequal variances based
on Satterthwaite calculations were used, and P < 0.05 was
considered significant in comparisons between strains of mice.
Challenge experiments of unimmunized and immunized mice
of both strains were repeated in three independent studies.
To determine the significance of the differences of antibody
levels between groups of mice, the log of the antibody titer for
each mouse in a group was used for statistical comparisons. A
two-factor analysis of variance based on mouse strain and
adjuvant was used to analyze the data. Pair-wise comparisons
were performed using Bonferroni adjustment for P values. P
values <0.01 were considered significant.
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